http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110922587-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d94573ab2c57e8b193f3a22accddf9fe |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G69-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5146 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G69-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9a0034ab07d8fbe1d67c48f5b4e4cbf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2981a0ea5808b54f55fe70942dc9739d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccd944da28b2193ba617b8ee89dd26e6 |
| publicationDate | 2020-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110922587-A |
| titleOfInvention | A kind of preparation method of nanometer medicine and its application in the treatment of osteosarcoma |
| abstract | The invention discloses a preparation method of nanometer medicine and its application in the treatment of osteosarcoma. The Cys-8E material synthesized by the invention has good biocompatibility and strong drug-carrying ability. After encapsulating Apatinib and GSK-J4 into a nano-drug (NP J4+Apa ), the nanocarrier can target the tumor site of osteosarcoma, and has better drug delivery ability for osteosarcoma stem cells that traditional drugs cannot. The nano-drug NP J4+Apa can induce apoptosis of osteosarcoma stem cells and significantly improve the therapeutic effect of Apatinib and GSK‑J4. At the same time, the nano-drug NP J4+Apa can prevent Apatinib and GSK‑J4 from acting on normal cells and reduce their toxic side effects. The nanomedicine NP J4+Apa of the present invention has the advantages of targeting osteosarcoma stem cells and less side effects, and has good application prospects and broad development space in the clinical field of osteosarcoma. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111763315-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111763315-A |
| priorityDate | 2019-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.